Press Releases

Date Title and Summary  
Toggle Summary Geron Announces Presentations at American Society of Hematology Annual Meeting
Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes to be Presented MENLO PARK, Calif. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that four abstracts related to the telomerase inhibitor imetelstat have been accepted for presentation
Toggle Summary Geron Announces Fast Track Designation Granted to Imetelstat for Lower Risk Myelodysplastic Syndromes
Expanded Part 1 of IMerge is Open for Patient Enrollment MENLO PARK, Calif. , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that the United States Food and Drug Administration ( FDA ) has granted Fast Track designation to imetelstat for the potential treatment of
Toggle Summary Geron Announces Conference Call to Discuss Third Quarter 2017 Financial Results
MENLO PARK, Calif. , Oct. 25, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the third quarter ended September 30, 2017 , on Wednesday, November 1, 2017 , after the market close. Geron’s management will also host a conference call for analysts and
Toggle Summary Geron to Present at the Cantor Fitzgerald Healthcare Conference
MENLO PARK, Calif. , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett , M.D., President and Chief Executive Officer, is scheduled to present at the Cantor Fitzgerald Global Healthcare Conference in New York at 1:40 p.m.
Toggle Summary Geron Corporation Reports Second Quarter 2017 Financial Results
MENLO PARK, Calif. , Aug. 09, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the three and six months ended June 30, 2017 . For the second quarter of 2017, the company reported a net loss of $6.4 million , or $0.04 per share, compared to $8.6 million ,
Toggle Summary Geron Announces Updates to Imetelstat Clinical Development
Conference Call Scheduled for 8:00 a.m. ET on Tuesday, August 1 MENLO PARK, Calif. , July 31, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced updates to the clinical development plans for IMerge and IMbark, the ongoing trials of the telomerase inhibitor imetelstat in lower
Toggle Summary Geron Corporation Reports First Quarter 2017 Financial Results and Recent Events
MENLO PARK, Calif. , May 09, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the first quarter ended March 31, 2017 and recent events. First Quarter 2017 Results For the first quarter of 2017, the company reported operating revenues of $537,000 and
Toggle Summary Geron 2017 Annual Meeting of Stockholders to be Held on May 9
First Quarter 2017 Financial Results Expected Same Day MENLO PARK, Calif. , April 25, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will hold its 2017 Annual Meeting of Stockholders, on Tuesday, May 9, 2017 , at 4:00 p.m. PDT . Geron’s stockholders are invited to attend the Annual
Toggle Summary Geron Announces Completion of Second Internal Data Reviews for Imetelstat Trials Being Conducted by Janssen
Both IMerge and IMbark Continue in Lower Risk Myelodysplastic Syndromes and Relapsed or Refractory Myelofibrosis Conference Call Scheduled for 8:00 a.m. EDT Today, April 10 MENLO PARK, Calif. , April 10, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that Janssen Research
Toggle Summary Geron Announces Conference Call on April 10 at 8:00 A.M. Eastern Time
MENLO PARK, Calif. , April 09, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will host a conference call on April 10, 2017 , at 8:00 a.m. Eastern Time to provide an update on the ongoing imetelstat Phase 2/3 trial in myelodysplastic syndromes and the Phase 2 trial in myelofibrosis.